Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Research Question:
Is the drug RP1 alone and in combination with nivolumab safe and well tolerated in adult subjects with advanced and/or refractory solid tumors?

Basic Study Information

Purpose:
RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and to generate an anti-tumor immune response. This is a first-in-human clinical study to evaluate the safety and tolerability of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors.

Location: University of Rochester Medical Center
Study Reference #: IMLT19000

Lead Researcher (Principal Investigator)

Lead Researcher:  Rachael Turner

Study Contact Information

Study Coordinator: Katherine Gerich
Phone: (585) 486-0592
Email: Katherine_Gerich@URMC.Rochester.edu

Additional Study Details

Return to Search